These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 9210034

  • 1. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma.
    Liu MY, Chang YL, Ma J, Yang HL, Hsu MM, Chen CJ, Chen JY, Yang CS.
    J Med Virol; 1997 Jul; 52(3):262-9. PubMed ID: 9210034
    [Abstract] [Full Text] [Related]

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [A comparison of the detection of IgM antibodies against the viral capsid antigen (VCA) of EBV (Epstein-Barr virus) in various groups of patients, using indirect immunofluorescence, indirect ELISA and reverse ELISA. Study of the diagnostic efficacy of the anti-VCA EBV IgM ELISA-VIDITEST kit].
    Pumannová M, Rezbová M, Svecová M, Hrbácková H, Novotná M, Ochotná J, Roubalová K.
    Klin Mikrobiol Infekc Lek; 2004 Aug 15; 10(4):186-90. PubMed ID: 15328576
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
    Chow KC, Ma J, Lin LS, Chi KH, Yen SH, Liu SM, Liu WT, Chen WK, Chang TH, Chen KY.
    Cancer Epidemiol Biomarkers Prev; 1997 May 15; 6(5):363-8. PubMed ID: 9149897
    [Abstract] [Full Text] [Related]

  • 9. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R, Menezes J, Drouet E, Joab I, Benider A, Bakkali H, Kanouni L, Jouhadi H, Benjaafar N, El Gueddari B, Hassar M, Khyatti M.
    J Clin Virol; 2008 Feb 15; 41(2):96-103. PubMed ID: 18024156
    [Abstract] [Full Text] [Related]

  • 10. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM.
    J Med Virol; 2005 Apr 15; 75(4):593-602. PubMed ID: 15714486
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, Jin YT, Lin JC.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):130-7. PubMed ID: 16979842
    [Abstract] [Full Text] [Related]

  • 12. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM.
    J Med Virol; 2007 Nov 01; 79(11):1710-21. PubMed ID: 17854043
    [Abstract] [Full Text] [Related]

  • 13. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
    Shimakage M, Ikegami N, Chatani M, Yoshino K, Sato T.
    Biken J; 1987 Jun 01; 30(2):45-51. PubMed ID: 2830879
    [Abstract] [Full Text] [Related]

  • 14. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC.
    Bull Cancer Radiother; 1996 Jun 01; 83(1):3-7. PubMed ID: 8679277
    [Abstract] [Full Text] [Related]

  • 15. [The purification and application of Epstein-Barr virus gp125].
    Wang G, Pi G, Gu S.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun 01; 12(2):143-6. PubMed ID: 12515193
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus seroepidemiology in China.
    Zeng Y, Pi GH, Deng H, Zhang JM, Wang PC, Wolf H, De Thé G.
    AIDS Res; 1986 Dec 01; 2 Suppl 1():S7-15. PubMed ID: 3030349
    [Abstract] [Full Text] [Related]

  • 17. Seroepidemiological study of Epstein-Barr virus infection in Bangladesh.
    Haque T, Iliadou P, Hossain A, Crawford DH.
    J Med Virol; 1996 Jan 01; 48(1):17-21. PubMed ID: 8825705
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma.
    Tang JW, Rohwäder E, Chu IM, Tsang RK, Steinhagen K, Yeung AC, To KF, Chan PK.
    J Clin Virol; 2007 Dec 01; 40(4):284-8. PubMed ID: 17977062
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
    Chen Y, Yao K, Sun H, Qing J, Peng GY.
    Chin Med J (Engl); 2005 May 05; 118(9):725-30. PubMed ID: 15899133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.